John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

HER2+ gastroesophageal adenocarcinomas: Current standards and therapeutic perspectives Volume 29, issue 4, April 2022

Tables

Authors
Institut de Cancérologie de Montpellier (ICM), Département d’Oncologie Médicale, Univ. Montpellier, Montpellier, 208 Avenue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 5
* Correspondance : S. Quesada

Esogastric adenocarcinomas (EGA) are characterized in 10-20 of cases by overexpression and/or amplification of HER-2. Current standard treatment for HER2+ EGA relies on trastuzumab (an anti-HER-2 antibody) plus a doublet of chemotherapy (fluoropyrimidine + platinum salt). For more than a decade, no obvious therapeutic progress has enriched the therapeutic arsenal for these patients, whether in the first-line with other anti-HER2 agents or in the context of trastuzumab resistance. The first results of studies based on trastuzumab-deruxtecan and immune checkpoint inhibitors are therefore likely to modify management practices for HER2+ AOG.